As of Thursday close, X4 Pharmaceuticals Inc.’s (NASDAQ:XFOR) stock was up $0.04, moving up 2.30 percent to $1.78. The average number of shares traded per day over the past five days has been 2,057,800 shares. 1 time new highs have been achieved over the past 5 days, with a $0.0800 gain in that time frame. In the last twenty days, the average volume was 1,939,460, while in the previous 50 days, it was 2,988,318.
Since last month, XFOR stock retreated -7.29%. Shares of the company fell to $1.6800 on 08/02/23, the lowest level in the past month. A 52-week high of $2.58 was reached on 06/13/23 after having rallying from a 52-week low of $0.65. Since the beginning of this year, XFOR’s stock price has risen by 79.25% or $0.7870, and marked a new high 23 times. However, the stock has declined by -30.87% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
XFOR stock investors should be aware that X4 Pharmaceuticals Inc. (XFOR) stock had its last reported insider trading activity 35 days ago on Jun 30. Mostafa Adam S., the Chief Financial Officer of the company, disposed of 2,641 shares for $1.89 on Jun 30. It resulted in a $4,991 divestment by the insider. DiBiase Mary sold 464 shares at an average price of $1.89 on Jun 30. The insider now owns 150,536 shares following the transaction. On Jun 23, President and CEO Ragan Paula sold 6,724 shares at $1.92 apiece. The transaction was valued at $12,910.
Financial Health
In the three months ended March 30, X4 Pharmaceuticals Inc.’s quick ratio stood at 5.00, while its current ratio was 5.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.62, and the total debt-to-equity ratio was 0.63. Based on annual data, XFOR earned $87.57 million in gross profit.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected X4 Pharmaceuticals Inc. to report -$0.22 quarterly earnings, the actual figure was -$0.16 per share, beating the consensus estimate by 27.30%. During the quarter, the company generated -$29.18 million in EBITDA. The liabilities of X4 Pharmaceuticals Inc. were 72.73 million at the end of its most recent quarter ended March 30, and its total debt was $36.93 million. The value of shareholders’ equity is $122.21 million.
Technical Picture
This quick technical analysis looks at X4 Pharmaceuticals Inc.’s (XFOR) price momentum. With a historical volatility rate of 51.09%, the RSI 9-day stood at 46.89% on 03 August.
With respect to its five-day moving average, the current X4 Pharmaceuticals Inc. price is up by +4.71% percent or $0.0800. At present, XFOR shares trade -3.78% below its 20-day simple moving average and +101.08% percent above its 100-day simple moving average. However, the stock is currently trading approximately -18.54% below its SMA50 and -11.88% below its SMA200.
Stochastic coefficient K was 26.20% and Stochastic coefficient D was 27.64%, while ATR was 0.1158. Given the Stochastic reading of 37.04% for the 14-day period, the RSI (14) reading has been calculated as 46.26%. As of today, the MACD Oscillator reading stands at -0.0122, while the 14-day reading stands at -0.0267.
Analyst Ratings
Cantor Fitzgerald launched its rating on X4 Pharmaceuticals Inc. (NASDAQ: XFOR) to an Overweight in a note to investors on December 22, 2022. X4 Pharmaceuticals Inc. (XFOR) has been rated Buy by analysts. According to 0 brokerage firms, XFOR is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate X4 Pharmaceuticals Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $4.00, the current consensus forecast for the stock is $2.60 – $5.00. Based on these forecasts, analysts predict X4 Pharmaceuticals Inc. (XFOR) will achieve an average price target of $3.76.
